1. Home
  2. IVDA vs AZTR Comparison

IVDA vs AZTR Comparison

Compare IVDA & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iveda Solutions Inc.

IVDA

Iveda Solutions Inc.

HOLD

Current Price

$1.04

Market Cap

4.5M

Sector

Technology

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.35

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVDA
AZTR
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
IVDA
AZTR
Price
$1.04
$0.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
9.2M
308.2K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,395,926.00
N/A
Revenue This Year
$340.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
20.56
N/A
52 Week Low
$0.61
$0.30
52 Week High
$8.05
$4.33

Technical Indicators

Market Signals
Indicator
IVDA
AZTR
Relative Strength Index (RSI) 47.59 40.19
Support Level $1.11 $0.34
Resistance Level $1.37 $0.39
Average True Range (ATR) 0.16 0.03
MACD 0.01 0.01
Stochastic Oscillator 33.15 46.47

Price Performance

Historical Comparison
IVDA
AZTR

About IVDA Iveda Solutions Inc.

Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: